Biological wound management

Aurase® is an enzymatic active ingredient developed by BRAIN Biotech for the treatment of open wounds. The active mechanism was inspired by the common green bottle fly.

The number of patients with chronic wounds is on the increase due to demographic change and diet-related diseases. It is an established fact that the larvae of the common green bottle fly promote wound debridement. Scientists at BRAIN Biotech have decoded the mechanisms behind this effect and developed the Aurase® enzyme for new wound treatment products, as a less invasive alternative to potentially very unpleasant forms of treatment such as surgical debridement.

BRAIN Biotech is able to produce the biological active ingredient in an ultrapure form. SolasCure Ltd., a company established with BRAIN’s participation, is currently preparing the certification and marketing of Aurase®.

Want to know more?

If you would like to talk to us about business opportunities or learn more about our development programs, please contact us.

Contact Business

40 m

There are more than 40 million patients with chronic wounds worldwide. Doctors speak of chronic cases when treatment takes longer than eight weeks. In Germany, the wounds of about one third of patients become chronic.

€ 10,000

The costs of treating patients with chronic wounds amount to € 2 – 4 billion each year in EU member states. Individual treatment costs are around € 10,000 per patient. Wound dressings and bandages account for about a fifth of these costs.

50 %

About half of all patients with decubitus ulcers (also known as bed-sores) and diabetic foot syndrome become chronic wound patients. Treatment may take many months or even years.

US$ 20 bn

Experts presume that the global market for wound treatment products and bandages will reach an annual volume of more than US$ 20 billion by 2020. The average annual growth rate of this market is estimated at eight per cent between 2014 and 2020.


  • is a new enzymatic active ingredient developed by BRAIN Biotech for the biological treatment of open wounds.
  • addresses the growing number of chronic wound patients.
  • offers an effective addition to other sometimes painful and unpleasant procedures such as surgical debridement.
  • illustrates the enormous potential of BRAIN Biotech’s Bioarchive and its biotechnology portfolio.
  • has already received patent coverage in some 20 countries.

Share this page